About David Moadel
David Moadel has provided compelling content – and crossed the occasional line – on behalf of Crush the Street, Market Realist, TalkMarkets, Finom Group, Benzinga, and (of course) InvestorPlace.com. He also serves as the chief analyst and market researcher for Portfolio Wealth Global and hosts the popular financial YouTube channel Looking at the Markets.
David Moadel proudly serves as the Chief Analyst and Opportunity Researcher for Portfolio Wealth Global as well as a financial writer for InvestorPlace.com. David is also active on multiple social media platforms, with tens of thousands of followers on YouTube, Twitter, StockTwits, and other popular sites. His YouTube channel educates and informs a loyal crowd of followers on topics ranging from cryptocurrencies to stocks, options, precious metals, bonds, futures, and other areas of finance. With a master’s degree in education and decades of investing experience, David has the financial know-how and a passion for teaching that has boosted the bottom line of countless clients. Focusing on data rather than emotions, David is always on the lookout for new pathways to financial freedom. Count on David for wealth-building strategies and resources for investors and traders of all financial backgrounds.
Recent Articles By David Moadel
$25 Is On Tap for SoFi Technologies as Analysts Pound the Table
There's high praise going around for SoFi (SOFI) as the company challenges traditional, outdated models of consumer finance.
$57 Price Target Could Be Just the Beginning for XPeng
Not everybody is enamored with Chinese stocks right now, but investors should consider investing in electric vehicle manufacturer XPeng (XPEV). Here’s why...
Planned Launches Should Add Fuel to Rocket Lab USA
Rocket Lab USA (RKLB) stock fell almost as quickly as it rose, but November should bring fresh space missions as well as higher share prices.
Progenity Stock Is a Zero-or-Hero Holding for Biotech Bidders
On the heels of a potent patent, short-squeeze target Progenity (PROG) offers excitement - and just maybe, outsized gains - for bold speculators.
Ignore Rumors, Stick to Facts and Hold DiDi Global
Don't hesitate to flex your contrarian muscles and invest in unloved DiDi Global (DIDI) - but first, do your due diligence and forget the FUD.
Currently Despised Farmmi Stock Could Soon Yield a Bumper Crop
Farmmi (FAMI) is trading at ultra-low prices, and contrarian investors are invited to dismiss the naysayers as Farmmi ramps up its sales.
Out-of-Control Expenses Make It Hard to Smile About SmileDirectClub
SmileDirectClub (SDC) stock may be the target of a pump job by social media traders, but sensible folks should give SmileDirectClub a checkup before investing.
Amazon Deal and Earnings Blowout Provide Affirmation for Affirm
"Buy now, pay later" services are coming into their own in the 2020's, and Affirm (AFRM) is leading the way.
After Nasdaq Uplisting, PharmaCyte Biotech Looks Ready to Rumble
There's no denying that PharmaCyte Biotech (PMCB) stock has lost much of its value over the years. However, recent developments could catalyze a price resurgence.